HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup

Chutes & Ladders-Legend CEO departs without successor in place

Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on founding CEO Fangliang Zhang, Ph.D.

By FierceBiotech · Aug 1, 2026 · via FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
Aug 1, 2026
FDA Expands Pluvicto Into Earlier PSMA-Positive Metastatic Prostate Cancer
The WeekBriefing
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …
Aug 1, 2026
The WeekFiercePharma ↗
Amylyx's patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a r…
Aug 1, 2026